Articles
-
-
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease
-
Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration
-
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics
-
Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity
Aims and scope
Molecular Neurodegeneration (MN) is an open access, peer-reviewed journal dedicated to publishing groundbreaking research in the field of neurodegeneration. Our mission is to foster a deeper understanding of neurodegenerative diseases, including but not limited to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, and macular degeneration, to inform novel diagnosis and effective therapy. We aim to publish innovative studies addressing the complex mechanisms of neurodegenerative disorders at the molecular, cellular, and systems levels, with a strong emphasis on broad impact and scientific rigor.
Collections
Glial and Vascular Contributions to Neurodegenerative Diseases
See Molecular Neurodegeneration's ongoing Collection on Glial and Vascular Contributions to Neurodegenerative Diseases.
ALS: Challenges and New Advances
See Molecular Neurodegeneration's ongoing Collection on ALS: Challenges and New Advances.
News from Alzforum
Follow
Annual Journal Metrics
-
2022 Citation Impact
15.1 - 2-year Impact Factor
15.8 - 5-year Impact Factor
3.022 - SNIP (Source Normalized Impact per Paper)
5.158 - SJR (SCImago Journal Rank)2023 Speed
30 days submission to first editorial decision for all manuscripts (Average)
143 days submission to accept (Average)2023 Usage
1,584,169 downloads
2,567 Altmetric mentions
Contact the Managing Editorial Team
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline